Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(2): 102–109. doi: 10.48095/ccgh2021102.

The importance of sarcopenia and frailty in the management of cirrhosis

Petra Vrbová1, Tomáš Koller1

+ Affiliation


At present, we have enough tools for quick and accurate assessment of the muscle strength and functional status of a patient with cirrhosis. In recent years, the diagnostic criteria for sarcopenia and frailty are gradually merging into one, primarily for practical reasons. Both of them are equally negative predictors of disease development in hospitalized patients with cirrhosis regardless of the decision on the indication of liver transplantation, but also in patients on the waiting list, and in those after liver transplantation. Sarcopenia and frailty are strong and disease stage-independent predictors of mortality. Undiagnosed and untreated sarcopenia or frailty also increase the risk of falls and fractures, impair the natural ability to perform daily activities, and increase the degree of dependence on others. They are associated with a reduced cognitive function, higher risk of complications, reduced quality of life and prolonged hospitalization. Their early identification will enable the optimization of patient management with the immediate use of nutritional support and pre-habilitation in order to prevent further deterioration of functional status and avoid adverse consequences of the disease.


liver cirrhosis, nutričný stav, sarkopénia, krehkosť, diagnosis, prognosis

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Pimpin L, Cortez-Pinto H, Negro F et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 2018; 69(3): 718–735. doi: 10.1016/j.jhep.2018.05.011.
2. Zdravotnícka ročenka Slovenskej republiky 2018. Bratislava: Národné centrum zdravotníckych informácií 2019.
3. European Association fot the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J  Hepatol 2018; 69(2): 406–460. doi: 10.1016/j.jhep.2018.03.024.
4. Skladaný L, Vnenčáková J, Laffers L et al. Adherence to oral nutritional supplements after being discharged from the hospital is low but improves outcome in patients with advanced chronic liver disease. Patient Prefer Adherence 2020; 14: 2559–2572. doi: 10.2147/PPA.S283034.
5. Kasper H. Výživa v medicíně a dietetika. 11. vyd. Praha: Grada 2015.
6. Kohout P et al. Vybrané kapitoly z klinické výživy II. Svazek IV. 1. vyd. Praha: Forsapi 2016.
7. Krajčík Š, Mikus P, Bajanová E et al. Výživa vo vyššom veku. Bratislava: Herba 2018.
8. Liguori I, Russo G, Aran L et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging 2018; 14(13): 913–927. doi: 10.2147/CIA.S149232.
9. Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010; 39(4): 412–423. doi: 10.1093/ageing/afq034.
10. Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48(4): 16– 31. doi: 10.1093/ageing/afy169.
11. Malmstrom TK, Miller DK, Simonsick EM et al. SARC‐F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016; 7(1): 28–36. doi: 10.1002/jcsm.12048.
12. Bharadwaj S, Ginoya S, Tandon P et al. Malnutrition: laboratory markers vs nutritional assessment. Gastroenterol Rep (Oxf) 2016; 4(4): 272– 280. doi: 10.1093/gastro/gow013.
13. Leonard J, Heimbach JK, Malinchoc M et al. The impact of obesity on long-term outcomes in liver transplant recipients – results of the NIDDK liver transplant database. Am J Transplant 2008; 8(3): 667–672. doi: 10.1111/j.1600-6143.2007.02100.x.
14. Topinková E. Sarkopenie jako závažné orgánové selhání, její diagnostika a současné možnosti léčby. Vnitř Lék 2018; 64(11): 1038–1052.
15. Guralnik JM, Simonsick EM, Ferrucci L et al. A short physical performance battery assessing lower extremity function: association with self­ -reported disability and prediction of mortality and nursing home admission. J Gerontol 1994; 49(2): M85–M94. doi: 10.1093/geronj/49.2.m85.
16. Bergland A, Strand BH. Norwegian reference values for the Short Physical Performance Battery (SPPB): the Tromsø Study. BMC Geriatr 2019; 19(1): 216. doi: 10.1186/s12877-019-1234-8.
17. Akin S, Mucuk S, Öztürk A et al. Muscle function-dependent sarcopenia and cut-off values of possible predictors in community-dwelling Turkish elderly: calf circumference, midarm muscle circumference and walking speed. Eur J  Clin Nutr 2015; 69(10): 1087–1090. doi: 10.1038/ejcn.2015.42.
18. Miller MD, Crotty M, Giles LC et al. Corrected arm muscle area: an independent predictor of long-term mortality in community-dwelling older adults? J Am Geriatr Soc 2002; 50(7): 1272–1277. doi: 10.1046/j.1532-5415.2002.50316.x.
19. Hida T, Ando K, Kobayashi K et al. Ultrasound measurement of thigh muscle thickness for assessment of sarcopenia. Nagoya J Med Sci 2018; 80(4): 519–527. doi: 10.18999/nagjms.80.4.519.
20. Carey EJ, Lai JC, Wang CW et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23(5): 625–633. doi: 10.1002/lt.24750.
21. Walowski CO, Braun W, Maisch MJ et al. Reference values for skeletal muscle mass – crrent concepts and methodological considerations. Nutrients 2020; 12(3): 755. doi: 10.3390/nu12030755.
22. Durand F, Buyse S, Francoz C et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60(6): 1151–1157. doi: 10.1016/j.jhep.2014.02.026.
23. Bahadori B, Uitz E, Tonninger-Bahadori K et al. Body composition: The fat-free mass index (FFMI) and distribution among the adult Austrian population-results of cross-sectional pilot study. Int J Body Compos Res 2006; 4(3): 123–128.
24. Skladaný Ľ, Kassová S, Šváč J. Syndróm krehkosti (frailty) v internej medicíne. Interná Med 2018; 18(6): 283–286.
25. Hoozová J. Krehkosť (frailty): spoločná téma geriatra a  paliatológa. Onkológia 2014; 9(6): 349–354.
26. Li H, Manwani B, Leng SX. Frailty, inflammation, and immunity. Aging Dis 2011; 2(6): 466–473.
27. Xue QL. The frailty syndrome: definition and natural history. Clin Geriatr Med 2011; 27(1): 1–15. doi: 10.1016/j.cger.2010.08.009.
28. Chen X, Mao G, Leng SX. Frailty syndrome: an overview. Clin Interv Aging 2014; 19(9): 433– 441. doi: 10.2147/CIA.S45300.
29. Laube R, Wang H, Park L et al. Frailty in advanced liver disease. Liver Int 2018; 38(12): 2117–2128. doi: 10.1111/liv.13917.
30. Katz S, Ford AB, Moskowitz RW et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914–919. doi: 10. 1001/jama.1963.03060120024016.
31. Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky Performance Status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 2013; 13: 72. doi: 10.1186/1472-6947-13-72.
32. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146–M156. doi: 10.1093/gerona/56.3.m.146.
33. Lai JC, Feng S, Terrault NA et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14(8): 1870–1879. doi: 10.1111/ajt.12762.
34. Lai JC, Sonnenday CJ, Tapper EB et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J  Transplant 2019; 19(7): 1896–1906. doi: 10.1111/ajt.15392.
35. Lai JC, Covinsky KE, Dodge JL et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66(2): 564–574. doi: 10.1002/hep.29219.
36. Steffl M, Sima J, Shiells K et al. The increase in health care costs associated with muscle weakness in older people without long-term illnesses in the Czech Republic: results from the Survey of Health, Ageing and Retirement in Europe(SHARE). Clin Interv Aging 2017; 12: 2003–2007. doi: 10.2147/CIA.S150826.
37. Cederholm T, Barazzoni R, Austin P et al. ESPEN guidelines on definitions and terminology of clinical nutrition. Clin Nutr 2017; 36(1): 49–64. doi: 10.1016/j.clnu.2016.09.004.
38. Vrbová P, Koller T. Sarkopénia v internej medicíne. Via Practica 2019; 16(2): 58–60.
39. Kim G, Kang SH, Kim MY et al. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PloS One 2017; 12(10): e0186990. doi: 10.1371/journal.pone.0186990.
40. Montano-Loza AJ, Meza-Junco J, Prado CM et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012; 10(2): 166–173. doi: 10.1016/j.cgh.2011.08.028.
41. Kumar V, Benjamin J, Shasthry V et al. Sarcopenia in cirrhosis: fallout on liver transplantation. J Clin Exp Hepatol 2020; 10(5): 467–476. doi: 10.1016/j.jceh.2019.12.003.
42. Golse N, Bucur PO, Ciacio O et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. Liver Transpl 2017; 23(2): 143–153. doi: 10.1002/lt.24671.
43. Tay L, Ding YY, Leung BP et al. Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults. Age (Dordr) 2015; 37(6): 121. doi: 10.1007/s11357-015-9860-3.
44. Ebadi M, Tandon P, Moctezuma-Velazquez C et al. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. J  Hepatol 2018; 69(3): 608–616. doi: 10.1016/j.jhep.2018.04.015.
45. Skladaný Ľ, Koller T, Molčan P et al. Prognostic usefulness of serum myostatin in advanced chronic liver disease: its relation to gender and correlation with inflammatory status. J Physiol Pharmacol 2019; 70(3): 357–368. doi: 10.26402/jpp.2019.3.03.
46. Praktiknjo M, Clees C, Pigliacelli A  et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin Transl Gastroenterol 2019; 10(4): e00025. doi: 10.14309/ctg000000000000025.
47. Skladaný Ľ, Kassová S, Šváč J. Syndróm krehkosti (frailty) u mužov hospitalizovaných na internom oddelení. Lekársky Obzor 2019; 68(8): 238–244.
48. Malinis MF, Chen S, Allore HG et al. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era. Ann Transplant 2014; 19: 478–487. doi: 10.12659/AOT.890934.
49. Orman ES, Ghabril M, Chalasani N. Poor performance status is associated with increased mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2016; 14(8): 1189–1195. doi: 10.1016/j.cgh.2016.03.036.
50. Tandon P, Tangri N, Thomas L et al. A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. Am J Gastroenterol 2016; 111(12): 1759–1767. doi: 10.1038/ajg.2016.303.
51. Tapper EB, Finkelstein D, Mittleman MA et al. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology 2015; 62(2): 584–590. doi: 10.1002/hep.27830.
52. Samoylova ML, Covinsky KE, Haftek M et al. Disability in patients with end-stage liver disease: results from the functional assessment in liver transplantation study. Liver Transpl 2017; 23(3): 292–298. doi: 10.1002/lt.24684.
53. Sinclair M, Poltavskiy E, Dodge JL et al. Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol 2017; 23(5): 899–905. doi: 10.3748/wjg.v23.i5.899.
54. Carey EJ, Steidley DE, Aqel BA et al. Six­-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 2010; 16(12): 1373–1378. doi: 10.1002/lt.22167.
55. Yadav A, Chang YH, Carpenter S et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant 2015; 29(2): 134–141. doi: 10.1111/ctr.12493.
56. Faustini Pereira JL, Galant LH, Rossi D et al. Functional capacity, respiratory muscle strength, and oxygen consumption predict mortality in patients with cirrhosis. Can J Gastroenterol Hepatol 2016; 2016: 6940374. doi: 10.1155/2016/6940374.
57. Lai JC, Dodge JL, Sen S  et al. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the functio­nal assessment in liver transplantation (FrAILT) study. Hepatology 2016; 63(2): 574–580. doi: 10.1002/hep.28316.
58. Dunn MA, Josbeno DA, Tevar AD et al. Frailty as tested by gait speed is an independent risk factor for cirrhosis complications that require hospitalization. Am J Gastroenterol 2016; 111(12): 1768–1775. doi: 10.1038/ajg.2016.336.
59. Tapper EB, Finkelstein D, Mittleman MA et al. Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology 2015; 62(2): 584–590. doi: 10.1002/hep.27830.
60. Bhanji RA, Carey EJ, Yang L et al. The long winding road to transplant: how sarcopenia and debilityimpact morbidity and mortality on the waitlist. Clin Gastroenterol Hepatol 2017; 15(10): 1492–1497. doi: 10.1016/j.cgh.2017.04.004.
61. Lai JC, Covinsky KE, McCulloch CE et al. The liver frailty index improves mortality prediction of the subjective clinician assessment in patients with cirrhosis. Am J Gastroenterol 2018; 113(2): 235–242. doi: 10.1038/ajg.2017.443.
62. Lai JC, Dodge JL, Kappus MR et al. A multicenter pilot randomized clinical trial of a home­ -based exercise program for patients with cirrhosis: the strength training intervention (STRIVE). Am J Gastroenterol 2020. Publish ahead of print. doi: 10.14309/ajg.0000000000001113.
63. Lai JC, Dodge JL, Kappus MR et al. Changes in frailty are associated with waitlist mortality in patients with cirrhosis. J Hepatol 2020; 73(3): 575–581. doi: 10.1016/j.jhep.2020.03.029.
64. Skladaný Ľ, Drotárová Z, Vnenčáková J et al. Applicability and prognostic value of frailty assessment tools among hospitalized patients with advanced chronic liver disease. Croat Med J 2021; 62(1): 8–16. doi: 10.3325/cmj.2021.62.

Kreditovaný autodidaktický test